Loading...

DYAI DYADIC INTERNATIONAL INC Investments/Divestments 8-K Filing

DYDC

DY

DYADIC INTERNATIONAL INC

(DYAI)

2023 8-K

Show Summary

Show Summary

Notice of Delisting

Financial Statements

Debt-Equity Swaps

Financial Results

Funding Announcement

Gates Foundation Grant

Management Appointment

Convertible Note Amendment

Quarterly Results

Agreement with Proliant Bio...

Agreement with Proliant Bio...

Annual Meeting Voting Results

Earnings Reports

Financial Results and Leade...

Securities Purchase Agreement

Financial Results Announcement

Collaboration Agreement

Termination of Agreement

Agreement with INZYMES for ...

Earnings Reports

Annual Meeting of Shareholders

Earnings Reports

Licensing Agreement with Ru...

Accountant Change

Financial Results Announcement

Bylaws Amendment

Update on COVID-19 Vaccine ...

Resignation of Accountant

Clinical Trial Initiation

Other Special Situation

External Links:

Dyadic International signed a Development and Exclusive License Agreement with INZYMES to develop and commercialize non-animal dairy enzymes, receiving an upfront payment of $0.6 million and potential success fees, milestones, and royalties.

AI Assistant

DYADIC INTERNATIONAL INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.